Select Location
What is your delivery location?
We need your delivery location to continue browsing
Select Location
We need your delivery location to continue browsing
Prescription Required
Cipla Ltd.
60 tablet in Bottle
Tofacitinib
Keep in cold place
Delivering To:
Overview
Tofajak tablets are a prescription regimen comprising tofacitinib 5mg. It is used in the treatment of patients suffering from severely active rheumatoid arthritis and psoriatic arthritis. This medication works by reducing the signs and symptoms of arthritis in patients who have shown no response to methotrexate. It helps to decrease the swelling in adult patients (over the age of 18 years). Tofajak 5mg Tablet is also used to treat patients with ulcerative colitis. Tofajak (Tofacitinib) is available in the form of oral-use tablets with a strength of 5mg.
Rheumatoid arthritis
Treatment of Ulcerative colitis
Treatment of Ankylosing spondylitis
Treatment of Rheumatoid arthritis
Treatment of Psoriatic arthritis
Alcohol
unsafe
Do not consume alcohol while taking Tofajak 5mg tablet.
Pregnancy
consult your doctor
Do not take Tofajak 5mg tablet without consulting the doctor, in case of pregnancy.
Breast Feeding
consult your doctor
Do not take Tofajak 5mg tablet if you're breastfeeding. Consultation of the doctor is advised.
Driving
danger
It is advisable not to drive or operate heavy machinery, you may feel dizzy as one of the side effects of Tofajak 5mg tablet.
Kidney
precaution
Do not take Tofajak 5mg tablet without a doctor's consultation in case of kidney problems.
Liver
precaution
Share your medical history with the doctor in case of liver disease before taking Tofajak 5mg tablet.
Following are the possible side effects that can occur during your treatment with tofajak 5mg tablet. Contact your medical practitioner immediately if any of the above-mentioned side effects appear.
Diarrhea
Headache
Dizziness
Drowsiness
Cough
Trouble breathing
Night sweatsSore throatFever
Chills
Stomach pain
Nausea
Vomiting
Itching
Night sweats
The dose of Tofajak 5mg tablet is recommended by the healthcare professional as per the patient’s health and requirements. These tablets are indicated for oral use. Swallow the tablets as a whole with water.
tofacitinib 5mg, the active ingredient of Tofajak tablets, is a partial and reversible Janus kinase (JAK) inhibitor that works to prevent the body from responding to cytokine signals. By inhibiting JAKs, this compound actively hinders the phosphorylation and activation of STATs. The JAK-STAT signaling pathway is involved in the transcription of cells that are involved in hematopoiesis, and immune cell function. Tofajak 5mg Tablet works therapeutically by causing inhibition against the JAK-STAT pathway to reduce the inflammatory response in the body. However, there is evidence to suggest that it may also achieve efficacy through other pathways.
If you miss a dose of Tofajak 5mg tablets, make sure to call your healthcare professional to learn the ways of managing the missed dose. Ask your doctor for methods of coping.
Tofajak 5mg tablet are a prescription regimen comprising Tofacitinib. It is used in the treatment of patients suffering from severely active rheumatoid arthritis and psoriatic arthritis.
The dose of Tofajak 5mg tablet is recommended by the healthcare professional as per the patient’s health and requirements. These tablets are indicated for oral use. Swallow the tablets as a whole with water.
Tofajak 5mg tablet can cause certain side effects, like headache, fever, chills, skin rash, dizziness, drowsiness, loss of appetite, etc.
The immune system is suppressed by this medicine, which raises the possibility of infections. If you have a fever or other symptoms of an illness, let your doctor know.
If symptoms of overdose occur, it becomes important to contact the nearest medical professional immediately for supportive care. Kindly do not ignore any symptoms.
Tofajak 5mg tablet are not recommended unless necessary in women who are pregnant or plan to get pregnant. Consult a medical professional.
At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.
Enjoy the convenience of fast home delivery, secure packaging, and affordable prices*—plus *special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.
Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.
We currently ship to:
Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!
Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: phase III, randomized, double blind, placebo-controlled study. (2023). BMJ / PubMed.
Efficacy and safety of tofacitinib in rheumatoid arthritis by previous treatment: post hoc analysis of phase II/III trials. (2024). Arthritis Research & Therapy.
Ekin, A., Misirci, S., İldemir, S., Coskun, B. N., Yagiz, B., Dalkilic, E., & Pehlivan, Y. (2024, November 18). Efficacy and safety of tofacitinib in rheumatoid arthritis: Nine years of real-world data. Clinical and Translational Science, 17(11), e70084. https://doi.org/10.1111/cts.70084
Integrated safety analysis of tofacitinib from Phase 2 and 3 trials of patients with ankylosing spondylitis. (2024). Advances in Rheumatology, 64, 87.
